Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1991 Oct;32(4):447–454. doi: 10.1111/j.1365-2125.1991.tb03929.x

The effects of a 5-HT2 receptor antagonist (ICI 169,369) on changes in waking EEG, pupillary responses and state of arousal in human volunteers.

D S Millson 1, S J Haworth 1, A Rushton 1, D Wilkinson 1, S Hobson 1, J Harry 1
PMCID: PMC1368604  PMID: 1958438

Abstract

1. ICI 169,369 (2-(2-dimethylamino ethylthio)-3-phenyl quinoline) is a potent selective competitive antagonist of the 5-HT2 receptor in animal models. Effects of ICI 169,369 as single oral doses (80 and 120 mg) separated by 1 week, on the power spectrum of waking EEG, dark adapted pupil responses and sedation score, were studied in a double-blind, placebo controlled, randomised cross over within subject comparison, in six healthy male volunteers. 2. Pupillary responses were measured using a portable infrared pupillometer following 15 min dark adaptation, assessing resting vertical pupil diameter (RPD), light constricted diameter (MPD) and recovered final diameter (FPD) at the end of a 3 s measurement cycle. 3. Both doses of ICI 169,369 produced a mean 36% (range 10-54%) decrease in log 10 power of the waking EEG alpha activity with eyes closed (P less than 0.02), and mean 38% (range 2-86%) increase in theta activity at 2 h compared with placebo. 4. Both 80 and 120 mg doses of ICI 169,369 reduced RPD by approximately 30% from a predose value of 6.25 mm (+/- 0.87; 95% CI) and from placebo values 6.41 mm (+/- 1.06) and 7.48 mm (+/- 1.49) at 3 and 5 h after dosing. MPD was reduced by 50% with the 120 mg dose at 5 h after dosing (placebo 5.2 mm; ICI 169,369 2.7 mm; P less than 0.05). FPD was significantly reduced (P less than 0.01) by both doses at 3 h after dosing.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
447

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blackburn T. P., Thornber C. W., Pearce R. J., Cox B. In vitro studies with ICI 169,369, a chemically novel 5-HT antagonist. Eur J Pharmacol. 1988 Jun 10;150(3):247–256. doi: 10.1016/0014-2999(88)90005-2. [DOI] [PubMed] [Google Scholar]
  2. Blauw G. J., van Brummelen P., Chang P. C., Vermeij P., van Zwieten P. A. Regional vascular effects of serotonin and ketanserin in young, healthy subjects. Hypertension. 1988 Mar;11(3):256–263. doi: 10.1161/01.hyp.11.3.256. [DOI] [PubMed] [Google Scholar]
  3. Cameron H. A., Waller P. C., Ramsay L. E. Ketanserin in essential hypertension: use as monotherapy and in combination with a diuretic or beta-adrenoceptor antagonist. Br J Clin Pharmacol. 1987 Dec;24(6):705–711. doi: 10.1111/j.1365-2125.1987.tb03235.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chiang T. S. Effects of intravenous infusions of histamine 5-hydroxytryptamine, bradykinin and prostaglandins on intraocular pressure. Arch Int Pharmacodyn Ther. 1974 Jan;207(1):131–138. [PubMed] [Google Scholar]
  5. Conn P. J., Sanders-Bush E. Regulation of serotonin-stimulated phosphoinositide hydrolysis: relation to the serotonin 5-HT-2 binding site. J Neurosci. 1986 Dec;6(12):3669–3675. doi: 10.1523/JNEUROSCI.06-12-03669.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cooper S. J., Abbott A. Clinical psychopharmacology may benefit from new advances in 5-HT pharmacology. Trends Pharmacol Sci. 1988 Aug;9(8):269–271. doi: 10.1016/0165-6147(88)90001-6. [DOI] [PubMed] [Google Scholar]
  7. Davies P. T., Steiner T. J. Serotonin S2 receptors and migraine: a study with the selective antagonist ICI 169,369. Headache. 1990 May;30(6):340–343. doi: 10.1111/j.1526-4610.1990.hed3006340.x. [DOI] [PubMed] [Google Scholar]
  8. De Clerck F., Van Nueten J. M. Platelet-mediated vascular contractions: inhibition of the serotonergic component by ketanserin. Thromb Res. 1982 Sep 15;27(6):713–727. doi: 10.1016/0049-3848(82)90009-3. [DOI] [PubMed] [Google Scholar]
  9. Fink M. Pharmacoelectroencephalography: a note on its history. Neuropsychobiology. 1984;12(2-3):173–178. doi: 10.1159/000118132. [DOI] [PubMed] [Google Scholar]
  10. Fozard J. R. MDL 72222: a potent and highly selective antagonist at neuronal 5-hydroxytryptamine receptors. Naunyn Schmiedebergs Arch Pharmacol. 1984 May;326(1):36–44. doi: 10.1007/BF00518776. [DOI] [PubMed] [Google Scholar]
  11. Goldstein J. M., Litwin L. C., Sutton E. B., Malick J. B. Effects of ICI 169,369, a selective serotonin2 antagonist, in electrophysiological tests predictive of antipsychotic activity. J Pharmacol Exp Ther. 1989 Jun;249(3):673–680. [PubMed] [Google Scholar]
  12. Idzikowski C., Cowen P. J., Nutt D., Mills F. J. The effects of chronic ritanserin treatment on sleep and the neuroendocrine response to L-tryptophan. Psychopharmacology (Berl) 1987;93(4):416–420. doi: 10.1007/BF00207228. [DOI] [PubMed] [Google Scholar]
  13. Idzikowski C., Mills F. J., James R. J. A dose-response study examining the effects of ritanserin on human slow wave sleep. Br J Clin Pharmacol. 1991 Feb;31(2):193–196. doi: 10.1111/j.1365-2125.1991.tb05514.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kemp J. A., Roberts H. C., Sillito A. M. Further studies on the action of 5-hydroxytryptamine in the dorsal lateral geniculate nucleus of the cat. Brain Res. 1982 Aug 26;246(2):334–337. doi: 10.1016/0006-8993(82)91187-8. [DOI] [PubMed] [Google Scholar]
  15. Kramer R., Rubicek M., Turner P. The role of norfenfluramine in fenfluramine-induced mydriasis. J Pharm Pharmacol. 1973 Jul;25(7):575–576. doi: 10.1111/j.2042-7158.1973.tb09161.x. [DOI] [PubMed] [Google Scholar]
  16. Lader M., Denney S. C. A double-blind study to establish the residual effects of zopiclone on performance in healthy volunteers. Int Pharmacopsychiatry. 1982;17 (Suppl 2):98–108. [PubMed] [Google Scholar]
  17. Larson M. D. Dilation of the pupil in human subjects after intravenous thiopental. Anesthesiology. 1981 Mar;54(3):246–249. doi: 10.1097/00000542-198103000-00013. [DOI] [PubMed] [Google Scholar]
  18. Link C. G., Leigh T. J., Fell G. L. Effects of granisetron and lorazepam, alone and in combination, on the EEG of human volunteers. Br J Clin Pharmacol. 1991 Jan;31(1):93–97. doi: 10.1111/j.1365-2125.1991.tb03863.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Longmore J., Banjar W., Bradshaw C. M., Szabadi E. Effects of a controlled-release formulation of trazodone on psychomotor and autonomic functions in healthy volunteers: comparison with trazodone (conventional formulation), amitriptyline and placebo. Eur J Clin Pharmacol. 1988;34(1):97–99. doi: 10.1007/BF01061427. [DOI] [PubMed] [Google Scholar]
  20. Moro F., Scapagnini U., Scaletta S., Drago F. Serotonin nerve endings and regulation of pupillary diameter. Ann Ophthalmol. 1981 Apr;13(4):487–490. [PubMed] [Google Scholar]
  21. Osborne N. N., Beaton D. W. Direct histochemical localisation of 5,7-dihydroxytryptamine and the uptake of serotonin by a subpopulation of GABA neurones in the rabbit retina. Brain Res. 1986 Sep 10;382(1):158–162. doi: 10.1016/0006-8993(86)90125-3. [DOI] [PubMed] [Google Scholar]
  22. Pazos A., Probst A., Palacios J. M. Serotonin receptors in the human brain--IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience. 1987 Apr;21(1):123–139. doi: 10.1016/0306-4522(87)90327-7. [DOI] [PubMed] [Google Scholar]
  23. Reimann I. W., Ziegler G., Ludwig L., Frölich J. C. Central and autonomic nervous system side effects of ketanserin. Arzneimittelforschung. 1986 Nov;36(11):1681–1684. [PubMed] [Google Scholar]
  24. SCHUMACHER H., CLASSEN H. G. [Neuropharmacological studies on the analysis of pupillar motor activity]. Albrecht Von Graefes Arch Ophthalmol. 1962;164:533–537. doi: 10.1007/BF00682800. [DOI] [PubMed] [Google Scholar]
  25. Sharpley A. L., Solomon R. A., Fernando A. I., da Roza Davis J. M., Cowen P. J. Dose-related effects of selective 5-HT2 receptor antagonists on slow wave sleep in humans. Psychopharmacology (Berl) 1990;101(4):568–569. doi: 10.1007/BF02244239. [DOI] [PubMed] [Google Scholar]
  26. Shur E., Checkley S., Delgado I. Failure of mianserin to affect autonomic function in the pupils of depressed patients. Acta Psychiatr Scand. 1983 Jan;67(1):50–55. doi: 10.1111/j.1600-0447.1983.tb00330.x. [DOI] [PubMed] [Google Scholar]
  27. Tobin A. B., Unger W., Osborne N. N. Evidence for the presence of serotonergic nerves and receptors in the iris-ciliary body complex of the rabbit. J Neurosci. 1988 Oct;8(10):3713–3721. doi: 10.1523/JNEUROSCI.08-10-03713.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Tortella F. C., Echevarria E., Pastel R. H., Cox B., Blackburn T. P. Suppressant effects of selective 5-HT2 antagonists on rapid eye movement sleep in rats. Brain Res. 1989 Apr 24;485(2):294–300. doi: 10.1016/0006-8993(89)90573-8. [DOI] [PubMed] [Google Scholar]
  29. Yoss R. E., Moyer N. J., Ogle K. N. The pupillogram and narcolepsy. A method to measure decreased levels of wakefulness. Neurology. 1969 Oct;19(10):921–928. doi: 10.1212/wnl.19.10.921. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES